291 related articles for article (PubMed ID: 33541393)
1. Effect of denosumab switched from bisphosphonates in preventing joint destruction in postmenopausal rheumatoid arthritis patients with anti-cyclic citrullinated peptide antibodies.
Mori Y; Izumiyama T; Kurishima H; Kamimura M; Baba K; Mori N; Itoi E
J Orthop Surg Res; 2021 Feb; 16(1):107. PubMed ID: 33541393
[TBL] [Abstract][Full Text] [Related]
2. Impact of switching oral bisphosphonates to denosumab or daily teriparatide on the progression of radiographic joint destruction in patients with biologic-naïve rheumatoid arthritis.
Ebina K; Hirao M; Hashimoto J; Matsuoka H; Iwahashi T; Chijimatsu R; Etani Y; Okamura G; Miyama A; Yoshikawa H
Osteoporos Int; 2018 Jul; 29(7):1627-1636. PubMed ID: 29574517
[TBL] [Abstract][Full Text] [Related]
3. Identifying the preferable rheumatoid arthritis subgroups for intervention with the anti-RANKL antibody denosumab to reduce progression of joint destruction.
Tanaka Y; Soen S; Ishiguro N; Yamanaka H; Yoneda T; Tanaka S; Ohira T; Nitta T; Okubo N; Genant H; van der Heijde D; Takeuchi T
RMD Open; 2020 Jul; 6(2):. PubMed ID: 32732353
[TBL] [Abstract][Full Text] [Related]
4. Denosumab significantly improves bone mineral density with or without bisphosphonate pre-treatment in osteoporosis with rheumatoid arthritis : Denosumab improves bone mineral density in osteoporosis with rheumatoid arthritis.
Nakamura Y; Suzuki T; Kato H
Arch Osteoporos; 2017 Sep; 12(1):80. PubMed ID: 28936606
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of denosumab with regard to bone destruction in prognostic subgroups of Japanese rheumatoid arthritis patients from the phase II DRIVE study.
Ishiguro N; Tanaka Y; Yamanaka H; Yoneda T; Ohira T; Okubo N; Genant HK; van der Heijde D; Takeuchi T
Rheumatology (Oxford); 2019 Jun; 58(6):997-1005. PubMed ID: 30602032
[TBL] [Abstract][Full Text] [Related]
6. The Efficacy of Denosumab in Patients With Rheumatoid Arthritis: A Systematic Review and Pooled Analysis of Randomized or Matched Data.
Hu Q; Zhong X; Tian H; Liao P
Front Immunol; 2021; 12():799575. PubMed ID: 35069583
[TBL] [Abstract][Full Text] [Related]
7. Beneficial effects of switching to denosumab from bisphosphonates or selective estrogen receptor modulators in postmenopausal women with type 2 diabetes and osteopenia/osteoporosis.
Miyoshi A; Kameda H; Nagai S; Nakamura A; Miya A; Takase T; Atsumi T; Miyoshi H
J Diabetes Investig; 2021 Jul; 12(7):1293-1300. PubMed ID: 33141482
[TBL] [Abstract][Full Text] [Related]
8. Effects of denosumab treatment on bone mineral density and joint destruction in patients with rheumatoid arthritis.
Mochizuki T; Yano K; Ikari K; Kawakami K; Hiroshima R; Koenuma N; Ishibashi M; Momohara S
J Bone Miner Metab; 2018 Jul; 36(4):431-438. PubMed ID: 28681148
[TBL] [Abstract][Full Text] [Related]
9. Effect of denosumab on Japanese patients with rheumatoid arthritis: a dose-response study of AMG 162 (Denosumab) in patients with RheumatoId arthritis on methotrexate to Validate inhibitory effect on bone Erosion (DRIVE)-a 12-month, multicentre, randomised, double-blind, placebo-controlled, phase II clinical trial.
Takeuchi T; Tanaka Y; Ishiguro N; Yamanaka H; Yoneda T; Ohira T; Okubo N; Genant HK; van der Heijde D
Ann Rheum Dis; 2016 Jun; 75(6):983-90. PubMed ID: 26585988
[TBL] [Abstract][Full Text] [Related]
10. Effects of the anti-RANKL antibody denosumab on joint structural damage in patients with rheumatoid arthritis treated with conventional synthetic disease-modifying antirheumatic drugs (DESIRABLE study): a randomised, double-blind, placebo-controlled phase 3 trial.
Takeuchi T; Tanaka Y; Soen S; Yamanaka H; Yoneda T; Tanaka S; Nitta T; Okubo N; Genant HK; van der Heijde D
Ann Rheum Dis; 2019 Jul; 78(7):899-907. PubMed ID: 31036625
[TBL] [Abstract][Full Text] [Related]
11. The comparable efficacy of denosumab on bone mineral density in rheumatoid arthritis patients with postmenopausal osteoporosis: A retrospective case-control study.
Kim SK; Kim JW; Lee H; Park SH; Choe JY; Kim B
Medicine (Baltimore); 2023 Jun; 102(26):e34219. PubMed ID: 37390268
[TBL] [Abstract][Full Text] [Related]
12. Comparison of romosozumab versus denosumab treatment on bone mineral density after 1 year in rheumatoid arthritis patients with severe osteoporosis: A randomized clinical pilot study.
Mochizuki T; Yano K; Ikari K; Hiroshima R; Okazaki K
Mod Rheumatol; 2023 Apr; 33(3):490-495. PubMed ID: 35689558
[TBL] [Abstract][Full Text] [Related]
13. Assessment of the effects of switching oral bisphosphonates to denosumab or daily teriparatide in patients with rheumatoid arthritis.
Ebina K; Hirao M; Hashimoto J; Hagihara K; Kashii M; Kitaguchi K; Matsuoka H; Iwahashi T; Chijimatsu R; Yoshikawa H
J Bone Miner Metab; 2018 Jul; 36(4):478-487. PubMed ID: 28766140
[TBL] [Abstract][Full Text] [Related]
14. Comparison of Teriparatide and Denosumab in Patients Switching From Long-Term Bisphosphonate Use.
Lyu H; Zhao SS; Yoshida K; Tedeschi SK; Xu C; Nigwekar SU; Leder BZ; Solomon DH
J Clin Endocrinol Metab; 2019 Nov; 104(11):5611-5620. PubMed ID: 31265071
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of denosumab vs. bisphosphonates in postmenopausal women previously treated with oral bisphosphonates.
Miller PD; Pannacciulli N; Malouf-Sierra J; Singer A; Czerwiński E; Bone HG; Wang C; Huang S; Chines A; Lems W; Brown JP
Osteoporos Int; 2020 Jan; 31(1):181-191. PubMed ID: 31776637
[TBL] [Abstract][Full Text] [Related]
16. Effects of Denosumab in Japanese Patients With Rheumatoid Arthritis Treated With Conventional Antirheumatic Drugs: 36-month Extension of a Phase III Study.
Tanaka Y; Takeuchi T; Soen S; Yamanaka H; Yoneda T; Tanaka S; Nitta T; Okubo N; Genant HK; van der Heijde D
J Rheumatol; 2021 Nov; 48(11):1663-1671. PubMed ID: 33858976
[TBL] [Abstract][Full Text] [Related]
17. Effects after starting or switching from bisphosphonate to romosozumab or denosumab in Japanese postmenopausal patients.
Shimizu T; Arita K; Murota E; Hiratsuka S; Fujita R; Ishizu H; Asano T; Takahashi D; Takahata M; Iwasaki N
J Bone Miner Metab; 2021 Sep; 39(5):868-875. PubMed ID: 33847831
[TBL] [Abstract][Full Text] [Related]
18. Clinical effects of switching from minodronate to denosumab treatment in patients with postmenopausal osteoporosis: a retrospective study.
Kobayashi M; Sawada K; Yoshimura A; Yamamoto M; Shimizu A; Shimura K; Komura N; Miyamoto M; Ishida K; Kimura T
BMC Womens Health; 2020 Mar; 20(1):48. PubMed ID: 32138724
[TBL] [Abstract][Full Text] [Related]
19. Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates.
Miller PD; Pannacciulli N; Brown JP; Czerwinski E; Nedergaard BS; Bolognese MA; Malouf J; Bone HG; Reginster JY; Singer A; Wang C; Wagman RB; Cummings SR
J Clin Endocrinol Metab; 2016 Aug; 101(8):3163-70. PubMed ID: 27270237
[TBL] [Abstract][Full Text] [Related]
20. The clinical benefits of denosumab for prophylaxis of steroid-induced osteoporosis in patients with pulmonary disease.
Ishiguro S; Ito K; Nakagawa S; Hataji O; Sudo A
Arch Osteoporos; 2017 Dec; 12(1):44. PubMed ID: 28425086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
